First Page | Document Content | |
---|---|---|
Date: 2015-06-19 09:17:30Monoclonal antibodies Immunosuppressants Immunology Biotechnology Immune system Adalimumab Tocilizumab Infliximab Monoclonal antibody therapy Disease-modifying antirheumatic drug TNF inhibitor Rheumatology | TABLE OF CONTENTS INTRODUCTION 2Add to Reading ListSource URL: www.abirisk.euDownload Document from Source WebsiteFile Size: 758,62 KBShare Document on Facebook |
BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, biDocID: 1rrNB - View Document | |
Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2DocID: 1rmwo - View Document | |
EAP Reimbursement Criteria for Frequently Requested DrugsDocID: 1rhhE - View Document | |
UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include: Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certolDocID: 1rakB - View Document | |
TABLE OF CONTENTS INTRODUCTION 2DocID: 1qY7G - View Document |